-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Decline in Short Interest
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Decline in Short Interest
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) saw a significant drop in short interest in December. As of December 30th, there was short interest totalling 15,400 shares, a drop of 34.2% from the December 15th total of 23,400 shares. Approximately 1.1% of the company's shares are short sold. Based on an average trading volume of 511,700 shares, the short-interest ratio is currently 0.0 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Renaissance Technologies LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 93,619 shares of the company's stock, valued at approximately $58,000. Renaissance Technologies LLC owned 0.74% of Kiora Pharmaceuticals at the end of the most recent reporting period.
Get Kiora Pharmaceuticals alerts:Kiora Pharmaceuticals Stock Down 3.4 %
KPRX traded down $0.12 on Thursday, hitting $3.37. The company had a trading volume of 35,439 shares, compared to its average volume of 714,915. The company has a market cap of $3.85 million, a PE ratio of -0.06 and a beta of 0.26. Kiora Pharmaceuticals has a 12-month low of $2.32 and a 12-month high of $39.18. The business's fifty day simple moving average is $3.68 and its 200 day simple moving average is $8.35.
Kiora Pharmaceuticals (NASDAQ:KPRX – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported ($4.35) EPS for the quarter. On average, analysts anticipate that Kiora Pharmaceuticals will post -19.58 earnings per share for the current fiscal year.About Kiora Pharmaceuticals
(Get Rating)
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Kiora Pharmaceuticals (KPRX)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) saw a significant drop in short interest in December. As of December 30th, there was short interest totalling 15,400 shares, a drop of 34.2% from the December 15th total of 23,400 shares. Approximately 1.1% of the company's shares are short sold. Based on an average trading volume of 511,700 shares, the short-interest ratio is currently 0.0 days.
Kiora Pharmicals, Inc.(纳斯达克股票代码:KPRX — 获取评级)在12月份的空头利率大幅下降。截至12月30日,空头利率共计15,400股,较12月15日的23,400股总额下降了34.2%。该公司约有1.1%的股票被卖空。根据511,700股的平均交易量,空头利率目前为0.0天。
Institutional Inflows and Outflows
机构流入和流出
A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Renaissance Technologies LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 93,619 shares of the company's stock, valued at approximately $58,000. Renaissance Technologies LLC owned 0.74% of Kiora Pharmaceuticals at the end of the most recent reporting period.
一家对冲基金最近购买了Kiora Pharmicals股票的新股份。Renaissance Technologies LLC在向美国证券交易委员会(SEC)提交的最新13F文件中称,该公司在第一季度收购了Kiora Pharmicals, Inc.(纳斯达克股票代码:KPRX — 获取评级)的新股份。该基金购买了该公司93,619股股票,价值约58,000美元。在最近的报告期结束时,文艺复兴科技有限责任公司拥有Kiora Pharmicals0.74%的股份。
Kiora Pharmaceuticals Stock Down 3.4 %
基奥拉制药股价下跌3.4%
KPRX traded down $0.12 on Thursday, hitting $3.37. The company had a trading volume of 35,439 shares, compared to its average volume of 714,915. The company has a market cap of $3.85 million, a PE ratio of -0.06 and a beta of 0.26. Kiora Pharmaceuticals has a 12-month low of $2.32 and a 12-month high of $39.18. The business's fifty day simple moving average is $3.68 and its 200 day simple moving average is $8.35.
周四,KPRX下跌0.12美元,至3.37美元。该公司的交易量为35,439股,而平均交易量为714,915股。该公司的市值为385万美元,市盈率为-0.06,beta值为0.26。Kiora Pharmicals创下12个月低点2.32美元,12个月高点为39.18美元。该公司的五十天简单移动平均线为3.68美元,其200天简单移动平均线为8.35美元。
About Kiora Pharmaceuticals
关于 Kiora 制药
(Get Rating)
(获取评分)
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Kiora Pharmicals, Inc是一家处于临床阶段的专业制药公司,在美国开发和商业化治疗眼科疾病的疗法。其主要产品是 KIO-301,这是一种潜在的视力恢复小分子,正在进行1期临床试验,可作为光开关,用于恢复遗传性和年龄相关性视网膜退行性疾病患者的视力。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Kiora Pharmaceuticals (KPRX)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 免费获取 StockNews.com 关于 Kiora Pharmicals(KPRX)的研究报告的副本
- 高股息收益的必和必拓认为中国将推动 “23” 的增长
- Airbnb是否准备像分析师所预测的那样上涨38%?
- 特斯拉汽车降价对TSLA股票意味着同样的吗?
- 微软裁员预示着其他科技公司的裁员?
- 快速购买 Fastenal 的理由不止一个
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收Kiora Pharmicals每日的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Kiora Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧